| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-625 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate |
1987-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1993-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1993-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0234888-B1 |
| titleOfInvention |
Process for producing human epidermal growth factor and analogs thereof |
| abstract |
Disclosed is a process for producing a fusion protein comprising epidermal growth factor (EGF) attached through a Glu-residue to a leader. Treatment ofthe fusion protein with a Staphylococcus aureus V8 protease specific for cleaving peptides at a Glu-linkage produces large amounts of the 53 amino acid EGF sequence.The treatment conditions optimize production of the 53 and 51 amino acid EGFs relative to shorter analogs, and take full advantage of the selectivity of the protease. |
| priorityDate |
1986-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |